April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Voriconazole for Management of Fungal Keratitis
Author Affiliations & Notes
  • Thushanthi Ramakrishnan
    Corneal Unit, Centre of Eye Research Australia, melbourne, Australia
    Royal Victorian Eye and Ear Hospital, Melbourne, Australia
  • Marios Constantinou
    Corneal Unit, Centre of Eye Research Australia, melbourne, Australia
  • Vishal Jhanji
    The Chinese University of Hong Kong, Hong Kong, Australia
    Corneal Unit, Centre of Eye Research Australia, Melbourne, Australia
  • Rasik Vajpayee
    Corneal Unit, Centre of Eye Research Australia, melbourne, Australia
    Royal Victorian Eye and Ear Hospital, Melbourne, Australia
  • Footnotes
    Commercial Relationships  Thushanthi Ramakrishnan, None; Marios Constantinou, None; Vishal Jhanji, None; Rasik Vajpayee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5855. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thushanthi Ramakrishnan, Marios Constantinou, Vishal Jhanji, Rasik Vajpayee; Voriconazole for Management of Fungal Keratitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5855.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Infectious keratitis is a leading cause of monocular blindness worldwide and fungal pathogens account for 6-50% of these ulcers1. Fungal keratitis however remains a therapeutic challenge to ophthalmologists. Currently there is no established gold standard treatment for fungal keratitis, and the challenges in management of these patients arise due to delays in making the correct diagnosis and the limited efficacy of existing antifungal therapies. Voriconazole is a newer-generation triazole and its use both systemically and topically in the management of fungal keratitis has raised new interest with promising reports in literature suggesting that these agents may overcome the shortcomings of currently available therapies. The aim of our study was to determine the effectiveness of voriconazole in the management of fungal keratitis. 1.Lalitha P, Sharpiro B, Srinivasan M. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis. Arch Ophthalmol. 2007;125:789-793

Methods: : A retrospective review was undertaken of all the patients who were treated with systemic and/or topical voriconazole for management of Fungal keratitis at the Royal Victorian Eye and Ear Hospital between 2002 and 2009.

Results: : A total of 27 patients were treated with systemic and/or topical voriconazole for fungal keratitis. 13 patients responded to treatment, 11 patients required a penetrating keratoplasty and 3 patients required enucleation. Fusarium species was the most common organism isolated (N = 7), followed by Candida species (N=5). Patients who responded to treatment were younger with a mean age 50.01±15.88 (Non-responders (NR) 67.56±12.22), had better visual acuity of 0.31 ±0.31 on presentation (NR 0.07 ±0.15), and were diagnosed earlier at 10.69±9.80 days (NR 12.93±15.14). Presence of a peripheral infiltrate and hypopyon were associated with a poor outcome.

Conclusions: : Voriconazole was effective in at least 50% of the cases in our series. It may work better in patients who are younger and present early for treatment.

Keywords: cornea: clinical science • cornea: basic science • wound healing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×